comparemela.com
Home
Live Updates
Urologic Oncology - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - Urologic oncology - Page 1 : comparemela.com
ASCO 2024: Treatment Outcomes for Patients with Ga68-PSMA-PET Prostate Cancer with or Without Conventional Imaging Correlates
ASCO 2024, Prostate Cancer, metastatic hormone-sensitive prostate cancer (mHSPC), Ga68-PSMA-PET, EA8191/INDICATE (NCT04423211).
United states
University of texas
Wadih issa
Julian chavarriaga
Postdoctoral gu oncology research
American society of clinical oncology
Department of internal medicine
University of texas southwestern
Division of hematology
Society of urologic oncology
University of toronto
Clinical oncology
Poster session
Genitourinary cancer
Research fellow
Internal medicine
ASCO 2024: Zanzalintinib (XL092) plus Nivolumab in Non-Clear Cell Renal Cell Carcinoma: The Randomized Phase 3 STELLAR-304 Study
ASCO 2024 phase III STELLAR-304 trial, combination of zanzalintinib (XL092) plus nivolumab in patients with non-clear cell renal cell carcinoma (nccRCC), tyrosine kinase inhibitor (TKI) sunitinib.
United states
Sumantak pal
Sumanta pal
American society of clinical oncology
Department of medical oncology
Society of urologic oncology
University of toronto
Therapeutics research
City of hope comprehensive cancer center
Clinical oncology
Annual meeting
South america
North america
Medical oncology
Hope comprehensive cancer center
Rashid sayyid
ASCO 2024: ADT Sparing Approaches in the Metastatic Hormone-Sensitive and Castrate-Resistant Spaces
discussed ADT-sparing approaches in both the metastatic castrate sensitive and resistant settings.
United states
New york
Memorial sloan kettering cancer center
Karen autio
Karena autio
European association of urology
American society of clinical oncology
Oncology group
National comprehensive cancer network
University of toronto
Society of urologic oncology
Genitourinary oncologist early drug development specialist
American urological association
Clinical oncology
Annual meeting
Prostate cancer consensus conference
ASCO 2024: Belzutifan in Patients with Advanced Clear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 2 LITESPARK-013 Study
ASCO 2024, advanced clear cell renal cell carcinoma (ccRCC), Belzutifan, LITESPARK-013 Study, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
United states
Georgetown university
District of columbia
Michael atkins
Michaelb atkins
University of toronto
Georgetown lombardi comprehensive cancer center
Department of medical oncology
Database consortium
Georgetown university medical center
Merck sharp dome
Society of urologic oncology
International metastatic
American society of clinical oncology
Clinical oncology
Annual meeting
ASCO 2024: A Multicenter Phase II Study of Modified FOLFIRINOX for First-Line Treatment for Advanced Urachal Cancer (ULTMA; KCSG GU20-03)
ASCO 2024 results of a multicenter phase II trial of modified FOLFIRINOX for the first-line treatment of advanced urachal cancer (ULTMA; KCSG GU20-03), Urachal cancer is a rare malignancy accounting for 1% of bladder cancers.
United states
South korea
Soult ukpyolsi
Jae lyun lee
Md anderson cancer center
Society of urologic oncology
American society of clinical oncology
University college of medicine
Asan medical center
University of toronto
Clinical oncology
Annual meeting
University college
Rashid sayyid
Urologic oncology
Clinical fellow
vimarsana © 2020. All Rights Reserved.